C. Jeffrey Dekker - Dec 8, 2022 Form 4 Insider Report for ARCA biopharma, Inc. (ABIO)

Role: Chief Financial Officer
Signature: /s/ C. Jeffrey Dekker
Stock symbol: ABIO
Transactions as of: Dec 8, 2022
Transactions value $: $0
Form type: 4
Date filed: 12/9/2022, 03:30 PM
Previous filing: Dec 16, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABIO	Common Stock	Award	$0	+40K		$0.00	40K	Dec 8, 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares issued as restricted stock units (an "RSU") under the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The RSUs vest one year from December 8, 2022, subject to continuing employment with the Company through that date. In the event of a change in control of the Issuer or the grantee's involuntary termination without cause or by the grantee for good reason, 100% of the unvested RSUs shall become fully and immediately vested upon the closing date of such change in control or such involuntary termination date, respectively (to the extent such unvested RSUs have not yet then vested).

Content

Represents shares issued as restricted stock units (an "RSU") under the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The RSUs vest one year from December 8, 2022, subject to continuing employment with the Company through that date. In the event of a change in control of the Issuer or the grantee's involuntary termination without cause or by the grantee for good reason, 100% of the unvested RSUs shall become fully and immediately vested upon the closing date of such change in control or such involuntary termination date, respectively (to the extent such unvested RSUs have not yet then vested).